COMPANY OVERVIEW

None

---

LOCATION

---

THERAPEUTIC AREAS

---

WEBSITE

https://trigrrx.com

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

PRESS RELEASES

May 13, 2021

Compass Therapeutics, Inc. to Acquire TRIGR Therapeutics, Inc.

Jan 20, 2021

TRIGR Therapeutics and Elpiscience Biopharmaceuticals Announce $117 Million Exclusive China Licensing Transaction for TR009, a Phase 1B Dual Angiogenic Bispecific Antibody Targeting DLL4/VEGF

Jan 6, 2021

TRIGR Therapeutics Announces Publication of TR009/ABL001, Dual Angiogenic Bispecific Antibody Targeting VEGF/DLL4, in the International Journal of Molecular Sciences

For More Press Releases

---